COVID-19 has accelerated the use of digital therapeutics solutions as healthcare systems shift towards remote care.

In this session, we are looking to discuss the following questions:

• Evidence generation: Like a drug or not like a drug?

  The rigor in evidence expected of DTx should be second to no drug, given their role as a ‘therapeutic’. But can DTx companies run large, expensive, multi-year trials like pharma? What is the alternative?

• What are scalable and sustainable business models?

  Partnering with Pharma can only take us so far - what commercialization models have worked or not worked so far? Why have some failed?

• What does a successful  pricing and reimbursement look like?

• The poster children for DTx are chronic diseases and mental health.

  But are there other untapped opportunities to explore? What about chronic disease management makes it DTx- suited?

• What is the role of HCPs in patient on-boarding and retention?

  A DTx is only as good as its usage. In the absence of a label of dosing and side effects, how should HCPs get involved in prescribing and ensuring adherence to DTx?

• Do patients really want to use digital therapeutics?

• How to regulate DTx as SaMD

We are looking forward to speaking to you in this session. Just click on ‘register to join’. You can also find at the top of the page already signed up participants as well as insights to dive into.